Moderna, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Moderna, Inc. (MRNA) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $13.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-07-31
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $13.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $9.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $1.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $0.00.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $13.00M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $9.00M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $1.00M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.00M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $2.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $6.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $1.00M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $9.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $11.00M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $4.00M 10-K · filed 2025-02-21 |
| 2023-09-30 | $14.00M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $46.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $59.00M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $241.00M 10-K · filed 2024-02-23 |
| 2022-09-30 | $373.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $357.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $271.00M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $52.00M 10-K · filed 2023-02-24 |
| 2020-12-31 | $152.00K 10-K · filed 2021-02-26 |
| 2020-09-30 | $509.00K 10-Q · filed 2020-10-30 |
| 2020-06-30 | $94.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $7.42M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $40.00K 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |